Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2370 (Opicapone) Phase 1 Bioequivalence and Levodopa Co‑administration Study
jRCT2080223527Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Opicapone tablet vs capsule pharmacokinetics and Effect of opicapone dose on levodopa exposure. Started May 2017; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080223527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223527.